» Articles » PMID: 3768240

Relationship Between Alpha 1-acid Glycoprotein and Distribution of Disopyramide and Mono-N-dealkyldisopyramide in Whole Blood

Overview
Specialty Pharmacology
Date 1986 Sep 1
PMID 3768240
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

The binding of disopyramide (DP) and mono-N-dealkyldisopyramide (MND) was measured by equilibrium dialysis in spiked whole blood (10 mumol l-1 DP or MND) from 50 patients having a serum concentration of alpha 1-acid glycoprotein (AAG) ranging from 0.40 to 3.14 g l-1, as well as in whole blood from five healthy subjects, spiked with different concentrations of AAG ranging from 0.61 to 3.33 g l-1. The binding ratio (moles bound divided by moles unbound) in all samples increased from 1.0 to 8.0 for DP and 0.6 to 3.3 for MND with increasing AAG concentrations. The binding varied according to the AAG concentrations both in patients and healthy subjects. Similarly total and free plasma concentrations of DP and MND were also measured. With increasing AAG concentrations the total concentrations measured increased from 9.0 to 15.9 mumol l-1 for DP and from 6.8 to 11.8 mumol l-1 for MND whereas the free concentrations decreased from 3.8 to 0.5 mumol l-1 for DP and from 5.0 to 2.0 mumol l-1 for MND. With increasing AAG concentrations the whole blood/plasma concentration ratio decreased from 1.11 and 1.47 to 0.63 and 0.85 for DP and MND respectively. The ratio between their concentration in cells and the unbound concentration in plasma, however, was constant over the whole AAG concentration range. The mean ratios for all samples were 3.0 and 3.1 for DP and MND respectively, indicating that both compounds are bound or distributed to the blood cells. The distribution of the drugs in whole blood changed according to increasing AAG concentrations.(ABSTRACT TRUNCATED AT 250 WORDS)

Citing Articles

Disopyramide. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiac arrhythmias.

Brogden R, Todd P Drugs. 1987; 34(2):151-87.

PMID: 3304965 DOI: 10.2165/00003495-198734020-00001.


Effects of cardiovascular disease on pharmacokinetics.

Rodighiero V Cardiovasc Drugs Ther. 1989; 3(5):711-30.

PMID: 2577313 DOI: 10.1007/BF01857622.

References
1.
Fremstad D, Bergerud K, Haffner J, Lunde P . Increased plasma binding of quinidine after surgery: a preliminary report. Eur J Clin Pharmacol. 1976; 10(6):441-4. DOI: 10.1007/BF00563081. View

2.
Hermansson J, Eriksson M, Nyquist O . Determination of (R)- and (S)-disopyramide in human plasma using a chiral alpha 1-acid glycoprotein column. J Chromatogr. 1984; 336(2):321-8. DOI: 10.1016/s0378-4347(00)85155-5. View

3.
David B, Madsen B, Ilett K . Plasma binding of disopyramide. Br J Clin Pharmacol. 1980; 9(6):614-8. PMC: 1430006. DOI: 10.1111/j.1365-2125.1980.tb01090.x. View

4.
Piafsky K . Disease-induced changes in the plasma binding of basic drugs. Clin Pharmacokinet. 1980; 5(3):246-62. DOI: 10.2165/00003088-198005030-00004. View

5.
Aitio M . Plasma concentrations and protein binding of disopyramide and mono-N-dealkyldisopyramide during chronic oral disopyramide therapy. Br J Clin Pharmacol. 1981; 11(4):369-75. PMC: 1401668. DOI: 10.1111/j.1365-2125.1981.tb01134.x. View